Voyager Therapeutics Q1 net income $124M on $150.5M collaboration revenue; cash $273.3M

Voyager Therapeutics, Inc.

2023-Q1 EPS reported $2.94 revenue$150,480,000

Net income of $124.0M in Q1 2023 vs net loss of $21.3M in Q1 2022; collaboration revenue $150.5M (vs $0.7M).
Cash, cash equivalents and marketable securities $273.3M as of March 31, 2023; plus $25M Novartis option payment received after quarter.
Neurocrine Biosciences strategic collaboration: $175M upfront, up to $1.5B development milestones, $2.7B commercial milestones.
Novartis exercised options for novel TRACER capsids: $25M payment, up to $600M milestones and royalties.
Anti-tau antibody program VY-TAU01; IND filing on track for H1 2024. SOD1 program lead candidate now expected H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Voyager Therapeutics, Inc. reported first quarter 2023 results: revenue $150.5 million, net income $124.0 million.

Period: first quarter 2023
Revenue: $150.5 million
Net income: $124.0 million
Result: reported results

Exact text from the filing

In January 2023, Grace E. Colón, Ph.D., also joined the Board of Directors. First Quarter 2023 Financial Results ● Collaboration Revenues: Voyager had collaboration revenue of $150.5 million for the first quarter of 2023, compared to $0.7 million for the same period in 2022. The increase was primarily due to revenue recognized during the first quarter of 2023 on the

View on SEC.gov

Browse all earnings releases →

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-008652

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.